Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Dec;38(12):3177-3182.
doi: 10.1007/s00345-020-03130-1. Epub 2020 Feb 18.

Analysis of age influence on oncological results and toxicity of BCG immunotherapy in non-muscle invasive bladder cancer

Wojciech Krajewski  1 , Oscar Rodríguez Faba  2 , Alberto Breda  3 , Francesca Pisano  3 , Sławomir Poletajew  4 , Andrzej Tukiendorf  5 , Romuald Zdrojowy  1 , Anna Kołodziej  1 , Juan Palou  3
Affiliations
Multicenter Study

Analysis of age influence on oncological results and toxicity of BCG immunotherapy in non-muscle invasive bladder cancer

Wojciech Krajewski et al. World J Urol. 2020 Dec.

Abstract

Purpose: The aim of this study was to analyse the influence of age on the treatment outcome and toxicity in patients with T1HG non-muscle invasive bladder cancers treated with BCG immunotherapy.

Methods: Data from 637 patients with primary T1HG bladder cancer who were treated between 1986 and 2016 in two academic centres were retrospectively reviewed. Median follow-up was 57 months. Patients were divided into two groups: younger (< 70 years old) and older (≥ 70 years old). Additional analyses in subgroups of older (> 75 and > 80) patients were performed. Log-rank test, Cox regression analysis, and propensity score matching were performed to compare the groups.

Results: There were 389 patients below and 248 patients above or equal 70 years old. Recurrence-free, progression-free, and cancer-specific survival rates did not differ significantly between younger and older patients. Recurrence-free survival for younger and older patients were 55.4% vs 52.9%, progression-free survival 75.9% vs 76.6%, and cancer-specific survival were 87.5% vs 89.9% (all p > 0.05). Differences in the oldest subgroups also did not reach statistical significance. In both regression analysis and propensity score matching, no statistically significant associations of age with any of analysed end-points were found. Finally, there were no statistically significant differences between younger and older group in terms of moderate and severe complications occurrence (47.6% vs. 44.5%; p > 0.05) CONCLUSIONS: It was shown that increasing age was not associated with BCG immunotherapy oncological outcomes, or with BCG toxicity in T1HG non-muscle invasive bladder cancer.

Keywords: Age; BCG; Bladder cancer; Progression; Recurrence.

PubMed Disclaimer

Comment in

References

    1. Babjuk M, Bohle A, Burger M et al (2017) eau guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447–461. https://doi.org/10.1016/j.eururo.2016.05.041 - DOI - PubMed
    1. Shintani Y, Sawada Y, Inagaki T et al (2007) Intravesical instillation therapy with bacillus Calmette–Guerin for superficial bladder cancer: study of the mechanism of bacillus Calmette–Guerin immunotherapy. Int J Urol 14:140–146. https://doi.org/10.1111/j.1442-2042.2007.01696.x - DOI - PubMed
    1. DeVeale B, Brummel T, Seroude L (2004) Immunity and aging: the enemy within? Aging Cell 3:195–208. https://doi.org/10.1111/j.1474-9728.2004.00106.x - DOI - PubMed
    1. Pfister G, Savino W (2008) Can the immune system still be efficient in the elderly? An immunological and immunoendocrine therapeutic perspective. NeuroImmunoModulation 15:351–364. https://doi.org/10.1159/000156477 - DOI - PubMed
    1. Herr HW (2007) Age and outcome of superficial bladder cancer treated with bacille Calmette–Guerin therapy. Urology 70:65–68. https://doi.org/10.1016/j.urology.2007.03.024 - DOI - PubMed

Publication types

LinkOut - more resources